Infection, Immunity and Inflammation Research Gr

Infection, Immunity and Inflammation Research Group at Queen’s (3IQ)

Infectious agents have a major impact on global health. Recent data compiled by the World Health Organization indicate that upwards of 13.75 million people die each year due to infectious diseases – the leading cause of death on earth. These diseases caused by bacteria, fungi, viruses and other pathogens are also major causes of morbidity, and social and economic hardships for many millions more. The current influenza A H1N1 and HIV pandemics, the recent emergence of pathogens such as the SARS coronavirus, the re-emergence of bacterial pathogens such as M. tuberculosis, the increasing prevalence of once-controlled pathogens that are resistant to our antimicrobial drugs, and the frequency of sporadic outbreaks of highly virulent bacterial pathogens contaminating our food and water supplies are just a few examples that serve as important reminders of our vulnerability to infectious diseases. Furthermore, inflammation, a process closely associated with the clearance of infections, is also responsible for a large variety of human diseases. These disorders include allergy, cancer, cardiovascular disease and inflammatory intestinal diseases, to name a few.  These observations highlight the need for strong investment in research into infection, immunity and inflammation.

 Research in infection, immunity and inflammation will result in advances in our understanding of the basic biology of pathogens and the development of disease, the beneficial and detrimental aspects of the host response to infection, as well as the development of new diagnostic tools, vaccine strategies and pharmacological interventions.  The long term goals of researchers in this field are to eradicate pathogens and lessen the severity of disease, thereby preventing millions of deaths and improving the wellbeing of many more.

Members of the Infection, Immunity and Inflammation (3IQ) Research Group

  • Dr. John Allingham: Structure and function of cytoskeleton-associated molecular motors in human and agricultural fungal pathogens.
  • Dr. Bruce Banfield: Molecular and cellular biology of herpesvirus infections
  • Dr. Sam Basta: Virus-host interactions, focusing on the Immunobiology of antigen presenting cells and mechanisms of virus immune evasion during persistent infections.
  • Dr. Andrew Craig: Mast cell activation and inflammation
  • Dr. Anne Croy: Study of the local and systemic immune responses in pregnancy and in models of type 1 diabetes.
  • Dr. Anne Ellis:  The evaluation of systemic immune mechanisms at play in inflammation and allergic diseases.
  • Dr. Colin Funk: The role of lipid mediators in inflammatory disease
  • Dr. Katrina Gee: The impact of HIV infection on the function of immune cells.
  • Dr. Peter Greer:  Role of inflammation in cancer.
  • Dr. Zongchao Jia: Structure-function studies of proteins involved in infection and immunity.
  • Dr. Nancy Martin: Understanding how pathogenic bacteria sense and adapt to changes in their environment
  • Dr. Elaine Petrof: Microbial-epithelial cell interactions in the gut, and the effects of intestinal bacteria on inflammation.
  • Dr. Keith Poole: Mechanisms of antibiotics resistance in bacteria. Dr. Steven Smith: Structural and functional analysis of carbohydrate-modifying enzymes in Clostridium perfringens and structural and functional studies of E2A in lymphopoiesis.
  • Dr. Myron Szewczuk: The role of Neu1 sialidase in TLR activation and inflammation.
  • Dr. Chandra Tayade: Immune mechanisms in the pathogenesis of endometriosis.
  • Dr. Alan Lomax: Neuro-immune interactions during inflammatory disease.
  • Dr. Michael Rauh: Translational studies in myeloid blood cancers and innate immune tolerance.
  • Dr. Charles Graham: Inflammation in models of cancer and pregnancies.
  • Dr. Daren Heyland: End of life care, sepsis, and the interaction between the gastrointestinal tract, infection and nutrition in critical illness.
  • Dr. Christine Hough: immune tolerance to gene therapy with viral vectors.
  • Dr. David Lillicrap: immunologic tolerance to Factor VIII.